Hugel
Financials
Valuation Metrics
Hugel's Market Cap is ₩2.3T. At end of 2025 it was ₩2.9T. Ranked #169 of 2,410 in KR market (top 7%), #23 of 1,631 on KOSDAQ (top 1%), #11 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 5%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.29T KRW | KR#169/2,410 Sec#11/231 |
| Revenue | 479.57B KRW | KR#633/2,410 Sec#33/231 |
| Net Income | 163.22B KRW | KR#175/2,410 Sec#10/231 |
| Total Assets | 1.19T KRW | KR#434/2,410 Sec#23/231 |
| Net Assets | 1.09T KRW | KR#278/2,410 Sec#15/231 |
| Employees | 609 | KR#411/2,410 Sec#35/231 |
| Value | ||
| P/E | 14.01x | KR#1,058/2,410 Sec#63/231 |
| P/B | 2.10x | KR#2,007/2,410 Sec#152/231 |
| PEG | 1.51x | KR#783/2,410 Sec#50/231 |
| P/S | 4.77x | KR#2,147/2,410 Sec#145/231 |
| EV/EBITDA | 9.84x | KR#642/2,410 Sec#29/231 |
| FCF Yield | 5.97% | KR#823/2,410 Sec#42/231 |
| Profitability | ||
| ROE | 15.00% | KR#324/2,410 Sec#21/231 |
| ROA | 13.69% | KR#141/2,410 Sec#11/231 |
| Op. Margin | 43.56% | KR#17/2,410 Sec#5/231 |
| Revenue Growth | 18.88% | KR#578/2,410 Sec#54/231 |
| Earnings Growth | 9.30% | KR#761/2,410 Sec#50/231 |
| Financial Health | ||
| Debt Ratio | 9.57% | KR#129/2,410 Sec#28/231 |
| Total Debt | 26.30B KRW | KR#1,285/2,410 Sec#100/231 |
| FCF | 136.66B KRW | KR#146/2,410 Sec#6/231 |
| Cash | 259.56B KRW | KR#222/2,410 Sec#7/231 |
| Current Ratio | 7.55x | KR#158/2,410 Sec#34/231 |
| Net Debt/EBITDA | -1.12x | KR#359/2,410 Sec#18/231 |
| Performance | ||
| 1Y Return | -30.27% | KR#1,483/2,410 Sec#118/231 |
| 1M Return | 1.44% | KR#358/2,410 Sec#35/231 |
| From 52W High | -40.78% | KR#795/2,410 Sec#57/231 |
| 1Y MDD | -43.17% | KR#682/2,410 Sec#48/231 |
| Trading | ||
| Volume | 28,681 shares | KR#1,361/2,410 Sec#137/231 |
| Trading Value | 5.20B KRW | KR#291/2,410 Sec#26/231 |
| Foreign Own. | 58.53% | KR#21/2,410 Sec#1/231 |
| Per Share | ||
| EPS | 13,042 KRW | KR#85/2,410 Sec#6/231 |
| BPS | 86,924 KRW | KR#160/2,410 Sec#8/231 |
Company Info
Established in 2001, this global medical aesthetics company listed on KOSDAQ in 2015 and absorbed Hugel Pharma in 2018. Its core business involves the research, development, manufacturing, and sales of Type A botulinum toxin and hyaluronic acid fillers, including products like BOTULAX, The Chaeum, and Wellage. The company drives innovation through technologies such as artificial intelligence and robotics, providing comprehensive solutions for diverse aesthetic needs to enhance corporate value. Hugel was established in 2001 and is headquartered in Chuncheon-si, Gangwon Special Self-Governing Province.